Markets:

Overview

News

Currencies

International

Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

271.60 -8.40 (-3.00%)

Official Closing Price Updated: 4:15 PM EST, Jan 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Assessing Insulet: Insights From 6 Financial Analysts ↗

February 21, 2025

Via Benzinga

Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations

February 20, 2025

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 17.2% year on year to $597.5 million. Guidance for next...

Via StockStory

Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year

February 20, 2025

From Insulet Corporation

Via Business Wire

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Insulet Earnings: What To Look For From PODD

February 19, 2025

Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close. Here’s what to expect.

Via StockStory

Looking for growth without the hefty price tag? Consider NASDAQ:PODD. ↗

February 14, 2025

Based on Fundamental Analysis it can be said that NASDAQ:PODD is a growth stock which is not overvalued.

Via Chartmill

$1000 Invested In Insulet 10 Years Ago Would Be Worth This Much Today ↗

February 07, 2025

Via Benzinga

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today ↗

January 20, 2025

Via Benzinga

Why NASDAQ:PODD Is a Standout High-Growth Stock in a Consolidation Phase. ↗

February 06, 2025

Based on a technical and fundamental analysis of NASDAQ:PODD we ask: Why INSULET CORP (NASDAQ:PODD) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

NASDAQ:PODD—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗

January 15, 2025

Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

January 13, 2025

From Insulet Corporation

Via Business Wire

Stryker Had A Good Year Last Year; Here's How It's Looking For 2025 ↗

January 13, 2025

Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74.

Via Investor's Business Daily

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

January 10, 2025

From Insulet Corporation

Via Business Wire

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today ↗

January 03, 2025

Via Benzinga

Looking Into Insulet's Recent Short Interest ↗

December 30, 2024

Via Benzinga

Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices ↗

January 07, 2025

Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level.

Via Investor's Business Daily

Exploring the Growth Potential of NASDAQ:PODD as It Nears a Breakout. ↗

December 25, 2024

Why INSULET CORP (NASDAQ:PODD) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today ↗

December 17, 2024

Via Benzinga

Inari Medical Stock Gets RS Rating Upgrade ↗

December 11, 2024

On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72.

Via Investor's Business Daily

Decoding 11 Analyst Evaluations For Insulet ↗

December 11, 2024

Via Benzinga

Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court

December 04, 2024

From Insulet Corporation

Via Business Wire

Novocure Stock Earns 96 RS Rating ↗

December 03, 2024

On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73.

Via Investor's Business Daily

Peering Into Insulet's Recent Short Interest ↗

November 27, 2024

Via Benzinga

NASDAQ:PODD qualifies as a high growth stock and is consolidating. ↗

November 27, 2024

INSULET CORP (NASDAQ:PODD)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.

November 20, 2024

From Insulet Corporation

Via Business Wire

Insulet to Present at Upcoming Investor Conferences

November 15, 2024

From Insulet Corporation

Via Business Wire

Top 4 Health Care Stocks That May Plunge This Quarter ↗

November 11, 2024

Via Benzinga

S&P 500 Breaks 6,000 Points, Dow Soars Above 44,000, Small Caps Eye Strongest Week In 4 Years, Tesla Hits $1 Trillion: What's Driving Markets Friday? ↗

November 08, 2024

The S&P 500 index surged past the 6,000-point milestone, setting fresh record highs, and small-cap stocks are poised for their best weekly performance since April 2024 as investor optimism surrounding...

Via Benzinga

Topics Stocks

Insulet Soars Out Of Buy Zone As 'Beat-And-Raise Cadence' Continues ↗

November 08, 2024

Shares soared out of a buy zone after beating third-quarter forecasts and raising its outlook for 2024.

Via Investor's Business Daily

High growth, ROE and relative strength for NASDAQ:PODD, growth investors may appreciate this. ↗

November 08, 2024

Evaluating INSULET CORP (NASDAQ:PODD) for Growth Investment Opportunities.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.